Predictive Oncology Inc. (Formerly Precision Therapeutics) Names Amelia Warner, Pharm.D., RPh, as Interim Chief Operating Off...
June 12 2019 - 8:00AM
Predictive Oncology Inc. (Nasdaq: AIPT) (“Predictive Oncology” or
the “Company”), a company focused on applying artificial
intelligence to personalized medicine and drug discovery, announced
today it has appointed Amelia Warner, Pharm.D., RPh, as the interim
chief operating officer for its Helomics division.
Dr. Carl Schwartz, Predictive Oncology’s Chief Executive
Officer, commented, “Dr. Warner brings over 15 years of experience
building businesses in the space of personalized medicine to her
new role as interim chief operating officer for Helomics. Her
outstanding accomplishments in the fields of pharmacogenomics and
building biorepository programs with Children's Hospital of
Philadelphia, Schering-Plough, and Merck throughout her storied
career establish her as a highly valued member of our growing team.
Her demonstrated leadership optimizing genetic sample
collection, data generation, data transfer and establishing
international policy for both genetic specimens and human specimen
research will serve Predictive Oncology’s goals of bringing new
opportunities for drug discovery and advancing precision medicine.
We are excited about her ability to bring our virtual AI drug
discovery program to big pharma with her intimate understanding of
both the landscape and market needs. Her role on the
company’s Advisory Board has been highly productive and influential
as we pursue our AI-driven approach to personalized medicine.
Her understanding of the immense value of our tumor response data
and how to leverage it into pharma drug discovery programs is
incomparable and we are excited to move forward with her
stewardship in this senior management role.”
Prior to joining Helomics, Dr. Warner founded Global Specimen
Solutions, Inc. (GSS) in 2013, which radically improved
translational science through powerful new pipeline data management
analytics for global specimen data tracking for the pharmaceutical
industry. After rapid market uptake and growth, GSS was sold
to a public company in December 2017. Prior to GSS, Dr.
Warner served as CEO for Gentris Corporation, where she led a
financial and operational turnaround resulting in the successful
sale of Gentris to a public company. She has also served as
head of Clinical Pharmacogenomics and Clinical Specimen Management
for Merck Research Laboratories (MRL). In this role, she led
a data overhaul for the Clinical Translational Medicine program,
oversaw all clinical pharmacogenomics projects, as well as policies
and procedures for biosample collection and storage for clinical
trials samples. In addition, she has served as chair of the
Industry Pharmacogenomics Working Group (I-PWG) and was a PhRMA
representative to ICH E16- Genomic Biomarkers Related to Drug
Response.
Dr. Warner completed both a residency in pediatric
pharmacotherapy and a fellowship in clinical
pharmacology/pharmacogenomics at St. Jude Children’s Research
Hospital. She holds a BS in biology from Wake Forest
University and a Pharm.D. from the University of North Carolina at
Chapel Hill.
“Multiple firms, whether CRO or drug discovery platforms, claim
to have comprehensive data and an AI component, but Helomics’
unique, clinically validated, cell-based patient derived tumor
testing technology coupled with its massive database of both in
vitro drug response profiles paired with clinical outcome data will
provide its clients with intelligent designed AI powered multi-omic
predictive models of tumor drug response and drive our goal of
revolutionizing patient care - a distinct technological advantage,
that has yet to be fully recognized in the market,” added Dr.
Warner. “I look forward to collaborating with both management
and implementation teams at Helomics to deliver superior results
for our clients, and enhanced valuation for shareholders of
Predictive Oncology.”
“Dr. Warner brings world-class clinical pharmacogenomics
expertise and vast clinical research organization experience to her
new role as interim chief operating officer of Helomics, after
having served as an integral member of the company’s Advisory Board
since mid-2017. Our strong history of successes working
together at Gentris yielded tremendous outcomes, where we were able
to increase productivity and significantly enhance valuation.
Amelia’s new role will capitalize on her broad background as we
proceed in commercializing and monetizing our AI platform and
capabilities. Amelia’s background and capabilities will serve
these goals to drive the realization of Helomics’ vast potential,”
commented Gerald Vardzel, president of Helomics.
About Predictive Oncology Inc.Predictive
Oncology (formerly Precision Therapeutics Inc.) (Nasdaq: AIPT until
June 12, 2019; POAI starting June 13, 2019) operates through its
three business units, Helomics, TumorGenesis and Skyline Medical.
Helomics applies artificial intelligence to its rich data gathered
from patient tumors to both personalize cancer therapies for
patients and drive the development of new targeted therapies in
collaborations with pharmaceutical companies. Helomics’
CLIA-certified lab provides clinical testing that assists
oncologists in individualizing patient treatment decisions, by
providing an evidence-based roadmap for therapy. In addition to its
proprietary precision oncology platform, Helomics offers boutique
CRO services that leverage its TruTumor™, patient-derived tumor
models coupled to a wide range of multi-omics assays (genomics,
proteomics and biochemical), and an AI-powered proprietary
bioinformatics platform (D-CHIP) to provide a tailored solution to
its clients’ specific needs. Predictive Oncology’s TumorGenesis
subsidiary is developing a new rapid approach to growing tumors in
the laboratory, which essentially “fools” cancer cells into
thinking they are still growing inside a patient. Its proprietary
Oncology Discovery Technology Platform kits will assist researchers
and clinicians to identify which cancer cells bind to specific
biomarkers. Once the biomarkers are identified they can be used in
TumorGenesis’ Oncology Capture Technology Platforms which isolate
and help categorize an individual patient’s heterogeneous tumor
samples to enable the development of patient specific treatment
options. Helomics and TumorGenesis are focused on ovarian cancer.
Predictive Oncology’s Skyline Medical division markets its patented
and FDA cleared STREAMWAY System, which automates the collection,
measurement and disposal of waste fluid, including blood,
irrigation fluid and others, within a medical facility, through
both domestic and international divisions. The company has achieved
sales in five of the seven continents through both direct sales and
distributor partners. For more information, please
visit www.predictive-oncology.com.
Forward-looking Statements Certain of the
matters discussed in the press release contain forward-looking
statements that involve material risks to and uncertainties in the
Company’s business that may cause actual results to differ
materially from those anticipated by the statements made herein.
Such risks and uncertainties include (i) risks related to the
recent merger with Helomics, including the fact that the combined
company will not be able to continue operating without additional
financing; possible failure to realize anticipated benefits of the
merger; costs associated with the merger may be higher than
expected; the merger may result in disruption of the Company’s and
Helomics’ existing businesses, distraction of management and
diversion of resources; and the market price of the Company’s
common stock may decline as a result of the merger; (ii) risks
related to our partnerships with other companies, including the
need to negotiate the definitive agreements; possible failure to
realize anticipated benefits of these partnerships; and costs of
providing funding to our partner companies, which may never be
repaid or provide anticipated returns; and (iii) other risks and
uncertainties relating to the Company that include, among other
things, current negative operating cash flows and a need for
additional funding to finance our operating plan; the terms of any
further financing, which may be highly dilutive and may include
onerous terms; unexpected costs and operating deficits, and lower
than expected sales and revenues; sales cycles that can be longer
than expected, resulting in delays in projected sales or failure to
make such sales; uncertain willingness and ability of customers to
adopt new technologies and other factors that may affect further
market acceptance, if our product is not accepted by our potential
customers, it is unlikely that we will ever become profitable;
adverse economic conditions; adverse results of any legal
proceedings; the volatility of our operating results and financial
condition; inability to attract or retain qualified senior
management personnel, including sales and marketing personnel; our
ability to establish and maintain the proprietary nature of our
technology through the patent process, as well as our ability to
possibly license from others patents and patent applications
necessary to develop products; Predictive Oncology’s ability to
implement its long range business plan for various applications of
its technology; Predictive Oncology’s ability to enter into
agreements with any necessary marketing and/or distribution
partners and with any strategic or joint venture partners; the
impact of competition, the obtaining and maintenance of any
necessary regulatory clearances applicable to applications of
Predictive Oncology’s technology; and management of growth and
other risks and uncertainties that may be detailed from time to
time in the Company’s reports filed with the SEC, which are
available for review at www.sec.gov. This is not a solicitation to
buy or sell securities and does not purport to be an analysis of
Predictive Oncology’s financial position. See Predictive Oncology’s
most recent Annual Report on Form 10-K, and subsequent reports and
other filings at www.sec.gov.
Contacts:Investor RelationsCORE IRBret
Shapiro(212) 896-1203brets@coreir.com
MediaJules AbrahamCORE IRjulesa@coreir.com917-885-7378
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Sep 2023 to Sep 2024